- Report
- August 2024
- 200 Pages
Global
From €3521EUR$3,869USD£2,991GBP
- Report
- June 2024
- 183 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- July 2024
- 109 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- May 2024
- 128 Pages
Global
From €3641EUR$4,000USD£3,092GBP
- Report
- April 2025
- 215 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- June 2024
- 140 Pages
Africa, Middle East
From €3521EUR$3,869USD£2,991GBP
- Report
- June 2024
- 140 Pages
Asia Pacific
From €3521EUR$3,869USD£2,991GBP
- Report
- June 2024
- 140 Pages
Europe
From €3521EUR$3,869USD£2,991GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3521EUR$3,869USD£2,991GBP
- Report
- May 2024
- 100 Pages
Africa
From €1820EUR$2,000USD£1,546GBP
- Report
- January 2024
- 348 Pages
Global
From €5301EUR$6,028USD£4,350GBP
- Report
- December 2022
- 354 Pages
Global
From €4813EUR$5,474USD£3,950GBP
- Report
- November 2022
- 148 Pages
Global
From €5006EUR$5,500USD£4,252GBP
- Report
- September 2020
- 219 Pages
Global
From €3186EUR$3,500USD£2,706GBP
- Report
- July 2020
- 255 Pages
Global
From €3186EUR$3,500USD£2,706GBP
- Report
- July 2023
- 74 Pages
Global
From €5416EUR$5,950USD£4,600GBP
- Report
- August 2022
- 120 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- December 2023
- 140 Pages
Global
From €4050EUR$4,450USD£3,440GBP
- Report
- August 2022
- 120 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2958EUR$3,250USD£2,512GBP

The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more